Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Touraj Shokati, Marcel Hartmann, Baharak Davari, Jost Klawitter, Jelena Klawitter & Uwe Christians. (2020) Temsirolimus metabolic pathways revisited. Xenobiotica 50:6, pages 640-653.
Read now
Read now
Xingxian Luo, Taifeng Li, Ze Yu, Xuecai Xue, Haiyang Zhao, Na li, Liping Ma, Changqing Yang, Lin Huang & Wanyu Feng. (2019) The impact of azole antifungal drugs on imatinib metabolism in human liver microsomes. Xenobiotica 49:7, pages 753-761.
Read now
Read now
Ayorinde Adehin, Babatunde A. Adeagbo, Martin A. Kennedy, Oluseye O. Bolaji, Tiwalade A. Olugbade, Rahman A. Bolarinwa & Muheez A. Durosinmi. (2019) Inter-individual variation in imatinib disposition: any role for prevalent variants of CYP1A2, CYP2C8, CYP2C9, and CYP3A5 in Nigerian CML patients?. Leukemia & Lymphoma 60:1, pages 216-221.
Read now
Read now
Andrew Rowland, Madelé van Dyk, Arduino A. Mangoni, John O. Miners, Ross A. McKinnon, Michael D. Wiese, Angela Rowland, Ganessan Kichenadasse, Howard Gurney & Michael J. Sorich. (2017) Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure. Expert Opinion on Drug Metabolism & Toxicology 13:1, pages 31-49.
Read now
Read now
Articles from other publishers (9)
Chiara Dalle Fratte, Sara Gagno, Rossana Roncato, Jerry Polesel, Martina Zanchetta, Mauro Buzzo, Bianca Posocco, Elena De Mattia, Rachele Borsatti, Fabio Puglisi, Luisa Foltran, Michela Guardascione, Angela Buonadonna, Erika Cecchin & Giuseppe Toffoli. (2022)
CYP2D6
and
CYP2C8
pharmacogenetics and pharmacological interactions to predict imatinib plasmatic exposure in GIST patients
. British Journal of Clinical Pharmacology 89:3, pages 1089-1098.
Crossref
Crossref
He Yu & Raj K. Singh Badhan. (2023) The Application of Virtual Therapeutic Drug Monitoring to Assess the Pharmacokinetics of Imatinib in a Chinese Cancer Population Group. Journal of Pharmaceutical Sciences 112:2, pages 599-609.
Crossref
Crossref
Bethany D. Latham, D. Spencer Oskin, Rachel D. Crouch, Matthew J. Vergne & Klarissa D. Jackson. (2022) Cytochromes P450 2C8 and 3A Catalyze the Metabolic Activation of the Tyrosine Kinase Inhibitor Masitinib. Chemical Research in Toxicology 35:9, pages 1467-1481.
Crossref
Crossref
Joseph D. Tucci, Paul P. Pumuye, Nuala A. Helsby, Daniel T. Barratt, Percy P. Pokeya, Francis Hombhanje & Andrew A. Somogyi. (2018) Pharmacogenomics in Papua New Guineans. Pharmacogenetics and Genomics 28:6, pages 153-164.
Crossref
Crossref
Caroline Gay, Delphine Toulet & Pascal Le Corre. (2017) Pharmacokinetic drug-drug interactions of tyrosine kinase inhibitors: A focus on cytochrome P450, transporters, and acid suppression therapy. Hematological Oncology 35:3, pages 259-280.
Crossref
Crossref
Daniel T. Barratt, Hannah K. Cox, Andrew Menelaou, David T. Yeung, Deborah L. White, Timothy P. Hughes & Andrew A. Somogyi. (2016) CYP2C8 Genotype Significantly Alters Imatinib Metabolism in Chronic Myeloid Leukaemia Patients. Clinical Pharmacokinetics 56:8, pages 977-985.
Crossref
Crossref
Michiel C. Verboom, Loes Visser, Sander Kouwen, Jesse J. Swen, Jeroen Diepstraten, Ward F. Posthuma, Hans Gelderblom, Daniëlle van Lammeren & Erik B. Wilms. (2017) Influence of CYP2C8 polymorphisms on imatinib steady-state trough level in chronic myeloid leukemia and gastrointestinal stromal tumor patients. Pharmacogenetics and Genomics 27:6, pages 223-226.
Crossref
Crossref
Jie Gao, Xin Tian, Jun Zhou, Ming-Zhu Cui, Hai-Feng Zhang, Na Gao, Qiang Wen & Hai-Ling Qiao. (2017) From Genotype to Phenotype: Cytochrome P450 2D6-Mediated Drug Clearance in Humans. Molecular Pharmaceutics 14:3, pages 649-657.
Crossref
Crossref
Peter I. Mackenzie, Andrew A. Somogyi & John O. Miners. (2017) Advances in drug metabolism and pharmacogenetics research in Australia. Pharmacological Research 116, pages 7-19.
Crossref
Crossref